LOGIN  |  REGISTER
Assertio

Premier to Report Fiscal 2025 First-Quarter Results and Host Conference Call on November 5, 2024

October 10, 2024 | Last Trade: US$21.80 0.05 0.23

CHARLOTTE, N.C. / Oct 10, 2024 / Business Wire / Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2025 first quarter on Tuesday, November 5, 2024, at approximately 6:30 a.m. ET. The company will also host a conference call at 8:00 a.m. ET to discuss its financial results.

The live webcast and replay will be available in the Investors section of the company’s website at Events & Presentations. The webcast should be accessed 10 minutes prior to the conference call start time. The replay of the event will be available for one year following the conclusion of the live broadcast.

For those parties who do not have internet access, the conference call can be accessed by calling one of the below telephone numbers and asking to join the Premier, Inc. call:

 

Domestic participant dial-in number (toll-free):

 

(833) 953-2438

 

International participant dial-in number:

 

(412) 317-5767

About Premier, Inc.

Premier, Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,350 U.S. hospitals and health systems and approximately 325,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members, suppliers and other stakeholders to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Please visit Premier’s news and investor sites on www.premierinc.com, as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.

C4 Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB